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Abstract: Increased oxidative damage in the brain, which increases with age, is the cause of abnormal
brain function and various diseases. Ascorbic acid (AA) is known as an endogenous antioxidant
that provides neuronal protection against oxidative damage. However, with aging, its extracellular
concentrations and uptake decrease in the brain. Few studies have dealt with age-related functional
changes in the brain to sustained ascorbate supplementation. This study aimed to investigate
the susceptibility of hippocampal neurons to oxidative injury following acute and chronic AA
administration. Oxidative stress was induced by kainic acid (KA, 5 µM) for 18 h in hippocampal slice
cultures. After KA exposure, less neuronal cell death was observed in the 3 w cultured slice compared
to the 9 w cultured slice. In the chronic AA treatment (6 w), the 9 w-daily group showed reduced
neuronal cell death and increased superoxide dismutase (SOD) and Nrf2 expressions compared to
the 9 w. In addition, the 9 w group showed delayed latencies and reduced signal activity compared to
the 3 w, while the 9 w-daily group showed shorter latencies and increased signal activity than the 9 w.
These results suggest that the maintenance of the antioxidant system by chronic AA treatment during
aging could preserve redox capacity to protect hippocampal neurons from age-related oxidative stress.
Keywords: ascorbic acid; antioxidant; aging; organotypic hippocampal slice culture; neuroprotection
1. Introduction
Oxidative stress is caused by reactive oxygen species (ROS) and leads to structural and
functional cellular changes in neurons, including apoptosis and necrosis [1]. Neurons are
especially vulnerable to oxidative stress due to their high lipid content and high metabolic
rates. Under physiological conditions, ROS are removed by a cellular antioxidant defense
system that includes redox homeostasis and cellular signal transduction. Even though ROS
are considered as damaging agents, ROS generation is initially necessary for cell function,
as ROS act as intracellular messengers and serve as a platform for the transmission of
physiological cellular redox signals in mitochondria and the cellular environment [2,3].
However, over-produced ROS lead to an accumulation of excess oxidant radicals that
could damage the mitochondria and neuronal cells [4]. Increased ROS in the aging process
progressively reduces the maintenance of tissue homeostasis and increases the likelihood of
degenerative diseases. Studies on aging over the past several decades have shown that free
radicals and oxidative stress increase with age and cause age-related increases in oxidative
damage to many human cellular molecules [5]. These previous studies have implicated ROS
as a source of oxidative damage to DNA, proteins, and lipids [6–9]. Mitochondria-generated
ROS, as byproducts of mitochondrial respiration, are primary targets for oxidative damage
and play an important role in aging [10,11]. Vitamins C and E are the main dietary
antioxidants that protect erythrocytes from damage caused by ROS [12].
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Ascorbic acid (AA), also known as vitamin C, is more highly concentrated in the brain
than in other organs and plays an important role in neuronal differentiation and myelin
formation [13]. For normal homeostasis of the nervous system, AA is considered to be the
most important nutrient due to its crucial role in the brain’s antioxidant defense system
responsible for scavenging reactive oxygen and nitrogen species produced during cellular
metabolism [14,15]. High concentrations of AA have been observed predominantly in
neuron-rich areas of the hippocampus and neocortex in the human brain [16], and the
ascorbate content in neurons compared to glia appears to be significantly different [17].
Therefore, AA is very important for brain function and maintenance. Furthermore, many
degenerative central nervous system diseases, including Alzheimer’s disease, multiple scle-
rosis, Parkinson’s disease, and Huntington’s disease [18], as well as psychiatric disorders,
such as depression, anxiety disorders, and schizophrenia [13,14], are highly associated
with AA deficiency. Brain levels of α-tocopherol, ascorbate, and glutathione have all been
reported to decrease with aging, and the ascorbate level decrease was accompanied by
decreased ascorbate synthesis and altered ascorbate transport characteristics [19]. These
decreased ascorbate levels could either contribute to and/or result from the aging pro-
cess. Interestingly, Michels et al. [20] demonstrated that declines in hepatic ascorbate in
rats were associated with an age-related change in ascorbate uptake. Nevertheless, few
studies have dealt with age-related functional changes in the brain to sustained ascorbate
supplementation or the optical activity of neurons capable of restoring functional activity
using optical imaging.
To investigate the results according to age and AA treatment effects, the present study
evaluated the neuroprotective properties of ascorbate treatment for various age-related
oxidation states in hippocampal slices, as well as the difference between acute and chronic
administration of ascorbate during aging. In addition, optical images were used to evaluate
the functional role of ascorbate-rescued neurons after oxidative damage caused by kinetic
acid (KA).
2. Results
2.1. Different Neuroprotection Effects of AA
At 3 w or 9 w after hippocampal slice culture, 5 µM KA was applied for 18 h to induce
oxidative injury and was included in fresh medium (vehicle group). AA with medium was
replaced for 24 h after KA treatment (AA treatment). For the 9 w experiment groups, one
was treated daily with AA from week 3 to week 9 (9 w-daily), and the other was treated
only with medium from week 3 to week 9 (9 w). The experimental groups and the overall
design are presented in Figure 1.
Figure 2 shows the different neuroprotective effects of AA in 3 w, 9 w, and 9 w-daily
organotypic hippocampal slice cultures (OHSCs) before (Pre, 2A upper line) and 24 h
after oxidative injury. KA treatment (5 µM) led to progressive cell death in the CA3 area
of the hippocampus after 24 h (24 h, 2A bottom line). Hippocampal neurons in the 3 w
KA + AA group showed reduced propidium iodide (PI) uptake compared to the 3 w
KA + vehicle group. Similar to the results of 3 w group, the 9 w KA + AA and 9 w-daily KA
+ AA groups also showed decreased PI uptake compared to the 9 w KA + vehicle and 9 w-
daily KA + vehicle groups. These results indicate the neuroprotective effects of AA after KA
exposure. Statistical analysis of neuroprotective effects of AA is shown in Figure 2B. The
3 w KA + vehicle and KA + AA PI uptake values were significantly increased compared
to the 3 w normal PI uptake (normal: 3.01 ± 1.58, KA + vehicle: 90.03 ± 3.02, KA + AA:
33.33 ± 4.75). In addition, 9 w of KA + vehicle and KA + AA and 9 w-daily KA + vehicle
and KA + AA value were significantly increased (9 w normal: 3.80 ± 2.01, KA + vehi-
cle: 91.83 ± 2.33, KA + AA: 74.46 ± 4.50; 9 w-daily normal: 2.73 ± 1.38, KA + vehicle:
76.54 ± 3.68, KA + AA: 59.37 ± 3.78). Moreover, 9 w KA + AA group showed significantly
increased cell death compared to 3 w KA + AA group. These results indicate that the aging
group (9 w) was more vulnerable compared to the young group (3 w) to cell death and
less sensitive to the protective effect of AA treatment following an oxidative injury. In
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addition, 9 w-daily KA + vehicle and 9 w-daily KA + AA groups showed significantly
reduced PI uptake compared to 9 w KA + vehicle and 9 w KA + AA groups. These results
indicate that chronic AA treatment protects hippocampal neurons from KA-induced ox-
idative injury and that prolonged antioxidant treatment during the aging process has a
neuroprotective effect.
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medium for 6 w before studies began. 
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Figure 1. Experi ental design and paradig . rganotypic hippocampal slice cultures (OHSCs) were cultured for 3 w and
9 w. Slices were treated with propidium iodide (PI) 2 h before 5 µM kinetic acid (KA) treatment for al cultures (PRE). Al
received KA treatment except for the normal controls in each experimental group. After 18 h exposure to KA, the medium
containing KA was changed to a fresh culture medium containing 500 µM ascorbic acid (AA). PI uptake, Western blot, and
electrophysiological studies were conducted 24 h after AA treatment. Experimental groups were divided by culture time
and treatment type, such as 3 w, 9 w, and 9 w-daily. In the 9 w-daily group, 500 µM AA was added to the culture medium
for 6 w before studies began.
2.2. Activation of Antioxidant Signals by AA Treatment in Aging
In our aging model of OHSCs with time in culture, w observed age-r lated changes in
t e hippocampus. Synapsin-1 and PSD 95, pre- and post-synaptic c mponents implicated
in dendritic spin formation and neurotransmission, were observed o confirm the aging
stat ses of each cultu condition. PSD 95 expression was significantly reduced in the 9 w
group c mpared to 3 w gro , while the 9 w-daily group showed significantly higher PSD
95 expression than th 9 w group. For synapsin-1, the 9 w group showed markedly lower
expression levels than the 3 w and 9 w-daily groups. The expression levels of synapsin-1
and PSD 95 in the 9 w group was markedly reduced compared to the 3 w group, whic
indicated the age-related phenomena within the hippocampus in our aging model of
OHSCs. As for the chronic A treatment group, the expression levels of both synapsin-1
and PSD 95 proteins showed significant differences between the 9 w and 9 w-daily groups
(Figure 3A). These results indicated that chronic AA treatment conserved the decreases in
synaptic ability associated with neurodegeneration in aging.
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Figure 2. Neuroprotective effects of AA against KA-induced oxidative injury in hippocampal neurons. (A) Representative 
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ment (500 µM) showed no toxic effect in KA-untreated normal OHSCs (9 w-daily Normal). (B) KA treatment induced 
progressive cell death in the hippocampus compared to the normal group at each time point. After 24 h of AA treatment, 
PI signals in the CA3 area of the hippocampus were significantly reduced in the treated groups compared to no-treatment 
(vehicle) groups at each time point. After chronic AA treatment (9 w-daily), there was less cell death following the KA 
insult compared to the 9 w vehicle group, and the 9 w-daily AA treatment group also showed a significant decrease in the 
level of PI uptake compared to the 9 w AA treatment group. ** p < 0.01 compared to normal; † p < 0.05, †† p < 0.01 compared 
to vehicle; # p < 0.05, ## p < 0.01 comparing different time points: two-way ANOVA followed by Tukey’s post hoc compar-
ison. Scale bar: 500 µm. 
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Figure 2. Neuroprotective effects of AA against KA-induced oxidative injury in hippocampal neurons. (A) Representative
PI fluorescence images in OHSCs before (Pre) and 24 h after AA-treatment following oxidative injury. Representative images
of PI uptake, as a marker of cell death, showed the effects of AA treatment at different time points. AA-only treatment
(500 µM) showed no toxic effect in KA-untreated normal OHSCs (9 w-daily Normal). (B) KA treatment induced progressive
cell death in the hippocampus compared to the normal group at each time point. After 24 h of AA treatment, PI signals in the
CA3 area of the hippocampus were significantly reduced in the treated groups compared to no-treatment (vehicle) groups
at each ti e poin . After chroni AA treatment (9 w-daily), there w s l ss cell death foll ing the KA insult compared to
the 9 w vehicle group, and the 9 w-daily AA treatment group also showed significant decrease in the level of PI u take
compared to the 9 w AA treatment group. ** p < 0.01 compared to normal; † p < 0.05, †† p < 0.01 compared to vehicle;
# p < 0.05, ## p < 0.01 comparing different time points: two-way ANOVA followed by Tukey’s post hoc comparison. Scale
bar: 500 µm.
To observe the anti xidant role of prolonged AA treatment on cell survival, we
examined the expression of superoxide dismutase (SOD) and Nrf2, which are known to be
factors in ROS-related cell survival signaling. At 3 w, the expression levels of SOD protein
significantly increased in the KA + AA group compared to KA + vehicle group. In the
aging model, the 9 w KA + AA group showed significantly higher SOD levels than the
KA + vehicle group. Compared to the 3 w KA + AA group, the levels of SOD expression in
the 9 w KA + AA group were significantly reduced. Moreover, SOD protein significantly
increased in the 9 w-daily KA + AA group compared to the KA + vehicle group. The
9 w-daily KA + vehicle group also showed significantly increased SOD levels compared to
the 9 w KA + vehicle group (Figure 3B). Nrf2 expression reflects the susceptibility of the
brain to the damaging effects of ROS: the level of Nrf2 expression diminished with age, and
consequently, its neuroprotective effect decreased. The expression levels of Nrf2 protein
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decreased in the vehicle group compared to the normal group at 3 w. With aging, the 9 w
group showed no difference in Nrf2 expression between KA + AA and KA + vehicle groups.
Compared to 3 w, Nrf2 expression was significantly decreased at 9 w for both KA + AA
and KA + vehicle groups. In the 9 w-daily group, Nrf2 expression tended to be higher
compared to the 9 w treatment groups (Figure 3C).
2.3. Effect of AA on Neuronal Activity
We performed optical imaging to observe cellular activities to visualize the active
area based on the overall data and provide information on neuronal activation using
a voltage-sensitive dye (VSD). Typical signal transmission and the spatial distribution
of the cellular response after electrical stimulation in different age-related groups are
shown in Figure 4A. As shown in Figure 4A, KA-untreated hippocampal neurons (normal
groups at 3 w, 9 w, and 9 w-daily) demonstrated typical spatiotemporal changes using
Schaffer collateral/commissural stimulation. However, limited activation accompanied by
synaptic propagation was observed in the KA + vehicle group of OHSCs. In contrast, more
activation (indicating more propagation) was observed in the KA + AA group compared to
the KA + vehicle group in each age-related group.
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Figure 3. (A) Changes in synaptic protein expres i lt re ti e of OHSCs. PSD 95 and synapsin-1
expression levels significantly reduced at 9 w compared to 3 w. In the chronic AA treatment group,
the expression levels of PSD 95 and synapsin-1 proteins showed a significant difference between 9 w
and 9 w-daily groups. (B) Western blot analysis of SOD and Nrf2 in OHSCs following oxidative injury.
The expression of SOD in the vehicle group was significantly reduced compared to the normal group.
The expression of SOD significantly increased 24 h after 500 µM AA treatment in the 3 w and 9 w
groups, compared to the vehicle group. The chronic AA treatment (9 w-daily) group showed higher
SOD expression than the 9 w group. (C) The expression level of Nrf2 increased in the AA treatment
group compared to th veh cle group at 3 w. Th 9 w group show d no difference in Nrf2 expression
betw en the AA tr atment and vehicle groups. However, Nrf2 expression was significantly decreased
in both AA treatment and vehicle groups at 9 w compared to 3 w. In 9 w-daily groups, Nrf2 expression
tended to increase compared to 9 w. The horizontal axis indicates each experimental group (3 w, 9 w,
and 9 w-daily AA treatment), and the vertical axis represents the normalized level of each protein
expression (ratio of each antibody expression/β-actin expression). * p < 0.05, ** p < 0.01 compared to
normal, † p < 0.05, †† p < 0.01 compared to vehicle, # p < 0.05, ## p < 0.01 comparing different time
points: two-way ANOVA followed by Tukey’s post hoc comparison.
N1 latency, a sign of synaptic activation, increased in both KA + vehicle and KA + AA
groups compared to both 3 w and 9 w normal groups by optical signals. The statistical
analysis of the neuronal activity of AA is shown in Figure 4B. At 3 w, the AA treatment
group showed a significantly reduced latency compared to the KA + vehicle group (normal:
8.84 ± 0.91, KA + vehicle: 30.75 ± 3.66, KA + AA: 16.45 ± 0.97). In 9 w, there was no differ-
ence between KA + vehicle and KA + AA groups in N1 latency (9 w normal: 9.05 ± 0.64,
KA + vehicle: 26.93 ± 4.27, KA + AA: 23.23 ± 1.56). Meanwhile, N1 latencies in the 9 w-
daily groups were significantly shorter than those in the 9 w KA + vehicle and KA + AA
grou s (9 w-daily normal: 7.66 ± 0.46, KA + v hicle: 12.75 ± 2.52, KA + AA: 8.94 ± 0.81).
These results showed that the chronic treatment AA (9 w-daily) in the aged g oup af-
fected th neuronal activity s an indicati n of survival neuronal function (Figure 4B).
In the activation area in Figure 4C, the KA + AA group showed significantly activated
areas compared to the KA + vehicle group at 3 w (normal: 39.70 ± 3.81, KA + vehicle:
15.40 ± 3.58, KA + AA: 27.52 ± 3.00). In 9 w OHSCs, few activated areas were observed
around the stimulating electrode in both the KA + vehicle and KA + AA groups (9 w
normal: 38.41 ± 4.64, KA + vehicle: 9.39 ± 1.31, KA + AA: 14.38 ± 2.61). There was no
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difference between the 9 w-daily groups (9 w-daily normal: 37.81 ± 7.44, KA + vehicle:
26.37 ± 5.44, KA + AA: 30.90 ± 6.02). However, chronic AA treatment in the 9 w-daily
KA + AA group elicited significantly more activated areas than the 9 w KA + AA group.
In addition, the 9 w-daily KA + vehicle group showed significantly larger activated areas
compared to the 9 w KA + vehicle group (Figure 4C). Therefore, synaptic propagation was
better preserved and maintained after chronic AA treatment in the 9 w-daily group, and
this group showed less vulnerability to oxidative injury compared to other 9 w groups.
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side) is presented by an arrow below the wave form (rig t side) at each time point (a, before stimulation; b, peak of N1; c,
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intensity (% ∆F/F). The blue grid line shows the peak of the negative (N1) point, which was used to quantify the N1 latency.
A colored scale (color calibration) shows the changes in optical signals (upper-left side). Signal transmission indicating
spatiotemporal changes showed an increas in neuronal activity through long-lasting depolarization. The KA + vehicle
groups at each time point showed a few signs of activation, only in the focal stimulation area. Spatiotemporal changes,
reflecting the distribution of neuronal activity, increased after AA treatment. (B) Comparisons of optical signals in the
different exper mental groups by latency, an indication of basal synaptic tr nsmission. Latencies were significantly delayed
in the vehicle groups compared to normal groups at each time point. The latency of the optical signals was decreased in
AA-treated hippocampal slices compared to the vehicle group at 3 w. For chronic AA treatment, there was a significant
difference between the 9 w and 9 w-daily groups. (C) Quantification of pseudo-color activated areas that indicate neuronal
activities through neural propagation. The activation area was decreased in the vehicle groups compared to the normal
groups at each time point. In particular, the chronic AA-treated 9 w-daily group showed a significantly greater increase in
activation area compared to the acute 9 w group. * p < 0.05, ** p < 0.01 compared to normal, †† p < 0.01 compared to vehicle,
# p < 0.05, ## p < 0.01 comparing different time points: two-way ANOVA followed by Tukey’s post hoc comparison. Scale
bar: 500 µm.
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3. Discussion
Providing cells with AA as an exogenous antioxidant retards their uptake of en-
dogenous antioxidants. In agreement with previous research [21], AA treatment elicited
significant reductions in neuronal cell death, compared to vehicle, through a reduction in
ROS and oxidative stress by the activation of antioxidant pathways. However, the negative
effect of oxidative decay caused by ROS is considered to be an irreversible progression in
the biology of aging [22]. Research has shown that the number of neurons and astrocytes
remain constant over 21 days in vitro (DIV, 3 w) among OHSCs by cell density analysis and
that the density of synaptic contacts within 21 DIV OHSCs is two times higher than those
in 7 DIV OHSCs [23]. Moreover, DIV 21 cultures have been found to show similarities
to features of the acute slice at P21 [24]. Synapses formed in OHSCs arise from neurons
that survive explanation, and synaptic differences in OHSCs according to culture time
have been observed, with significant reductions in PSD 95 and evoked synaptic activity at
67-76 DIV [25]. In line with the study by Mielke et al. [25], we also observed significant
decreases in PSD 95 and synapsin-1 expressions, which were assessed to reflect age-related
phenomena within the hippocampus in our aging model of OHSCs.
Age-dependent changes in brain homeostasis and function occur gradually, particu-
larly by the combination of ROS and the aging brain’s impaired ability to repair increased
oxidative stress damage [26]. Although we observed decreased neuronal cell death with
acute AA treatment after 3 w and 9 w, compared to vehicle, PI uptake quantitation, as
an indicator of cell death, was significantly different (based on age) between the 3 w and
9 w AA treatment groups. The 9 w group showed more vulnerability to oxidative injury
and cell death compared to the 3 w group. Aging of the brain was also associated with
an increase in seizure susceptibility, as well as with seizure-induced neuronal damage,
after KA-induced oxidative injury [27,28]. While Siqueira et al. [19] reported that 2 weeks
of chronic supplementation with ascorbate was unable to protect the hippocampus from
age-related oxidative damage (H2O2), we observed that the 9 w-daily vehicle and 9 w-daily
AA treatment groups showed significantly greater reductions in cell death than did the 9 w
AA treatment group. As a consequence of aging, decreased ascorbate synthesis or altered
ascorbate transport characteristics [19] may explain this reduced neuroprotective effect of
acute AA treatment in the 9 w group compared to chronic AA treatment in the 9 w-daily
group. We hypothesized that chronic AA treatment may lead to persistent regulation
of reactions against increased reactive oxygen and nitrogen species with various target
molecules during aging, a period during which the antioxidant system appears to be less
functional in the brain. Mild prooxidant activity can enhance antioxidant defense systems
through Nrf2 signaling [29–31]. In this regard, chronic treatment of AA, which is not only
able to scavenge free radicals but also maintain an optimal ROS flow, may upregulate
cytoprotective enzymatic antioxidants, thus improving neuronal survival. Chronic treat-
ment of AA might act as a parahormetic phytochemical, which can be attributed to both
antioxidant and mild prooxidant activities that affect the intracellular antioxidant defense
system. As part of the antioxidant defense system, any decrease in SOD and Nrf2 levels
would result in increased ROS [32]. In our Western blot analysis, the expressions of SOD
and Nrf2 significantly decreased in the 9 w groups compared to the 3 w groups. Imbalances
in ROS production due to impaired expression of SOD and decreased levels of antioxidant
molecules occurred with aging, as well as in neurodegenerative diseases [33]. Similar to
the PI results, chronic AA treatment (9 w-daily AA treatment group) significantly increased
SOD levels. The neurons in the 9 w group suffered more severe attacks by free radicals
compared to the neurons with chronic AA treatment, and AA supplementation might have
scavenged free radicals from plasma directly. The present study indicates that the aging
brain is highly susceptible to hippocampal cell loss by KA-induced oxidative stress, and
that chronic AA treatment can aid the cellular antioxidant system against oxidative injury.
To assess neuronal survival and functional property, optical imaging of VSD was
used to examine synaptic changes and strength in OHSCs. Optical imaging data repre-
sent the visualization of electrical signals from the population activity of postsynaptic
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neurons in the activated area as a distribution map of stimulus-induced activities [34].
Here, the differences in activities of surviving neurons were examined between 3 w and
9 w slice cultures that underwent AA treatment after oxidative injury. The 9 w group
showed increased latencies of optical signals and less activated areas compared to the 3 w
group, indicating reduced functionality of surviving neurons. This result may be related
to decreased uptake of radiolabeled ascorbate in aged rats [19], as well as to a decline in
sodium-dependent ascorbate transport during the aging process [20]. Siqueria et al. [19]
reported a 40% decrease in radiolabeled 14C-ascorbate uptake in 11-month-old rats com-
pared to 4-month-old rats, and Michels et al. [20] described an age-related reduction in the
plasma transport of dietary ascorbate. Neurons have a 10-fold-higher level of ascorbate
than the glia, making them more sensitive to ascorbate deficiency and any reduction in total
antioxidant capacity in an older hippocampus [19]. The VSD activation area is dependent
on the spatial distribution of cellular responses to electrical stimulation. In this study,
we demonstrated enhanced synaptic transmission resulting from chronic AA treatment
in older 9 w OHSCs after oxidative injury. To our knowledge, there are no reports that
chronic AA supplementation protects hippocampal cells in the brain from the age-related
increases in susceptibility to oxidative damage. Therefore, with the optical recording results
demonstrating better survival of hippocampal neurons and their connections, chronic AA
supplementation may not only be neuroprotective, but also help restore the endogenous
antioxidant system with advancing age.
4. Materials and Methods
4.1. Organotypic Hippocampal Slices Cultures (OHSCs)
Animal experiments were approved by the Institutional Animal Care and Use Committee
of Yonsei University Health System (permit no.: 2018-0095, approval date: 8 May 2018). Post-
natal Sprague-Dawley rats (6–7 d) were used according to the method of Stoppini et al. [35].
We used 45 rat pups, and 40 hippocampal slices were used in each group (one batch
contained five hippocampal slices, n = 8 batches). Hippocampi were dissected and placed
in Gey’s salt solution (Sigma, Saint Louis, MO, USA) with glucose (6.5 mg/mL). Slices
(350 µm thick) were cut parallel to the transverse axis of the hippocampus using a chopper
(McIlwain tissue chopper; Mickle Laboratory Engineering Ltd., Surrey, UK). Millicell cul-
ture inserts (Millipore, Billerica, MA, USA) containing five slices were cultured in 6-well
plates with medium (50% opti-MEM, 25% HBSS, 25% horse serum, 6.5 mg/mL glucose,
pH adjusted to 7.2) for 3 w or 9 w.
4.2. Propidium Iodide (PI) Staining
To induce oxidative injury, 5 µM KA (Sigma) was applied for 18 h and was included
with fresh medium in 3 w or 9 w after hippocampal slice culture (KA + vehicle). AA with
medium was replaced for 24 h with 5 ug/mL of propidium iodide (PI) (5 µg/mL, Sigma),
which was added to the culture medium (KA + AA). In chronic AA treatment, OHSCs were
maintained in culture medium with 500 µM AA for 6 w before KA exposure (9 w-daily).
As previously described [36], neuronal death was assessed by quantifying the fluorescence
intensity of PI. This was based on the principle that PI is impermeable to normal plasma
membranes and cells, and when cells are damaged, they migrate to the nucleus, where they
form a complex with DNA, making the nucleus fluoresce. PI uptake images were captured
with a fluorescence microscope digital camera (BX-51, Olympus, Tokyo, Japan) and quanti-
fied with the MetaMorph Imaging System (Universal Image Co, Downingtown, PA, USA).
PI uptake was measured before (Pre) and 24 h after the application of drugs, and the value of
the measured fluorescence area was expressed [(24 h − Pre/full kill − Pre) × 100] as the % PI
uptake. N-methyl-D-aspartate (NMDA) (100 µM, Sigma) was applied to induce fulminant
death of pyramidal neurons (full kill) at the termination of each experiment [37,38]. AA
treatment alone (500 µM) showed no toxic effect in KA-untreated normal OHSCs (Normal
group) at 3 w or 9 w.
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4.3. Western Blot Analysis
Homogenized slice lysates were prepared with lysis buffer (PRO-PREPTM, Intron
Biotechnology, Burlington, MA, USA). Proteins were resolved by SDS-PAGE (100 µg/lane)
using 10% (w/v) polyacrylamide gels and transferred to PVDF membranes (Millipore).
Membranes were incubated with antibodies against anti-PSD 95 (1:5000, Abcam, Cam-
bridge, MA, USA); anti-synapsin I (1:3000, Abcam); superoxide dismutase (SOD) (1:7500,
Abcam); and Nrf2 (1:5000, Abcam) for 2 h at room temperature. As a loading control, mem-
branes were also probed with anti-β-actin antibody (1:10,000, Abcam). The reaction was
developed with an enhanced chemiluminescence Western blot analysis system (ECL, GE
Healthcare, Marlborough, MA, USA). Signal intensities were analyzed using a gel-scanning
integrated optical density software program (Multi-gauge 3.0, Fuji film, Tokyo, Japan).
4.4. Optical Recording
Hippocampal slices (n = 8) were stained with a voltage-sensitive dye (VSD) solu-
tion (Di-2-ANEPEQ, JPW114; Invitrogen, Carlsbad, CA, USA) [39]. Briefly, 0.2 mM Di-
2-ANEPEQ staining solution was applied to the OHSCs in the plexiglass mesh-attached
ring. The OHSCs were maintained in a humidified chamber with a mixture of O2 and
CO2 gases for 25 min. The OHSCs were rinsed with artificial cerebrospinal fluid (ACSF:
composition in mM: NaCl, 124; NaHCO3, 26; glucose, 10; KCl, 3; CaCl2, 2; MgCl2, 1; HEPES,
10; pH 7.4) by dipping them through the plexiglass mesh-attached ring and kept for at
least 1 h to be recovered before being used for the experiment. A stained hippocampal slice
was attached to the chamber glass, which was pre-coated with 0.01% polyethylenimine
for approximately 1 h and rinsed with distilled water. Stained OHSCs were stabilized in
the recording chamber, which was continuously perfused with ACSF at 31 ◦C bubbled
with mixed 95% O2 and 5% CO2 gases. The Schaffer collateral (SC)/commissural path-
way was stimulated with a bipolar electrode (CBBPE75, FHC Inc, Bowdoin, ME, USA).
Synaptic activity was observed using an optical imaging system (MiCAM02, Brain Vision
Inc., Tsukuba, Japan) with a high-speed CCD camera. Optical images were recorded with
512 frames (1890 ms total) for the test stimulation and acquired at a sampling rate of 3.7 ms
per frame. Trials were conducted every 20 s (0.05 Hz). Fluorescence intensity [∆F/F: the
change in the intensity of fluorescence (∆F) in each pixel relative to the initial intensity of
fluorescence (F)] was used to assess fractional changes in the amount of VSD fluorescence.
Activated areas were determined by averaging images (spatial filter: 3 × 3 pixels, cubic
filter: 3 × 3 pixels). Acquisition and analysis software (BV-Analyzer, Brain Vision Inc.) was
used to display and analyze the optical images.
4.5. Statistical Analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software, San
Diego, CA, USA). Data are expressed as means ± standard errors of the mean (SEM). The
data were evaluated by two-way analysis of variance (ANOVA) followed by Tukey’s
multiple-range post hoc comparisons. Differences were considered significant when
p-values were less than 0.05.
5. Conclusions
In this study, we demonstrated that chronic AA treatment has a neuroprotective
influence on KA-induced oxidative stress in an aging hippocampus model. Based on
PI staining, chronic AA treatment also reduced age-related neurotoxicity (9 w-daily AA
treatment), and this was similar to its influence on oxidative injury in younger hippocampi
(3 w AA treatment). Western blot analysis demonstrated that chronic AA treatment
activated SOD, a well-known detoxifying enzyme, compared to acute AA treatment in the
9 w group. Therefore, we have shown that chronic AA treatment increases antioxidant
activity and decreases neuronal cell death in this model. Using optical signals to observe the
functional recovery of surviving neurons, AA treatment decreased latencies of the optical
signal, indicating an increase in effective neuronal transmission. These results suggest that
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surviving neurons, protected by chronic AA treatment, show enhanced functional recovery
in this aging model.
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